Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benoîte Mery1, Chloé Rancoule2, Elise Rowinski1

  • 1Département d'oncologie médicale, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez Cedex, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.

Breast cancer (Tokyo, Japan)·2026
Same author

Adenoid cystic carcinoma of the breast: a case series of 26 patients.

Breast cancer research and treatment·2026
Same author

Feasibility of <i>TP53</i>-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS.

Cancers·2026
Same author

ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.

Breast cancer research and treatment·2026
Same author

Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles.

Biomedicines·2025
Same author

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

Stereotactic radiotherapy, using high doses per fraction, shows promise for treating metastatic renal cancer by overcoming radioresistance. This approach may enhance treatment efficacy when combined with targeted drugs.

Area of Science:

  • Radiation Oncology
  • Medical Oncology
  • Nephrology

Background:

  • Metastatic renal cancer has a poor prognosis due to limited treatment efficacy.
  • Renal cell carcinoma is traditionally radioresistant, with conventional radiotherapy showing minimal impact.

Purpose of the Study:

  • To explore advanced stereotactic radiotherapy approaches for overcoming renal cancer radioresistance.
  • To investigate the potential of high-dose-per-fraction radiotherapy in managing metastatic renal cancer.

Main Methods:

  • Utilizing technological advances in radiation oncology for stereotactic approaches.
  • Applying high doses per fraction in radiotherapy to elicit distinct biological responses.

Main Results:

Keywords:
Cancer du reinKidney cancerMetastasisMétastasesRadiobiologieRadiobiologyRadioresistanceRadiorésistanceRadiothérapieStereotacticradiotherapystéréotaxique

Related Experiment Videos

  • Stereotactic radiotherapy overcomes radioresistance mechanisms in renal cancer cells.
  • High fractional doses trigger endothelial apoptosis, leading to increased radiobiological effects and high response rates.

    • Conclusions:

    • High-dose-per-fraction radiotherapy offers a promising new avenue for managing metastatic renal cancer.
    • Combining stereotactic radiotherapy with targeted drugs presents new therapeutic opportunities.